Xarelto Lawsuits on the Rise in Tennessee; Link Drug With Risk of Internal Bleeding Injuries

A Tennessee resident has filed a wrongful death lawsuit in the Xarelto multidistrict litigation over his father’s death, allegedly due to complications from the use of the anticoagulant. The complainant alleges that his father died from an uncontrollable, irreversible internal bleeding event as a result of Xarelto side effects. Accusing drug manufacturers Bayer AG and Janssen Pharmaceuticals of failure to warn patients of the potential Xarelto bleeding side effects, the lawsuit claims that the deceased was prescribed the blood thinner to treat atrial fibrillation symptoms and prevent the risk of blood clots and stroke.

The plaintiff accuses the drug makers of intentionally misleading the medical community about the serious threats posed by the anticoagulant, which is unreasonably dangerous and defective. Introduced in the market in 2011, Xarelto claims to be a one-size-fits-all medication for deep vein thrombosis, strokes, and pulmonary embolism in patients suffering from atrial fibrillation.

Unfortunately, unlike other anticoagulants, Xarelto blood thinner does not respond to fresh frozen plasma and Vitamin K treatment, which is given as an antidote to allow the patient’s blood to clot in the event of internal bleeding. As a result, the use of Xarelto causes an unstoppable, fatal event of internal bleeding for the patient.

The complaint indicates that Xarelto’s dangerous lack of antidote raises the risk of potentially fatal gastrointestinal bleeding episodes. The lawsuit accuses defendants Bayer and Janssen of pushing direct-to-consumer advertising, claiming that Xarelto was safer than other blood thinners and also required less monitoring and doctor visits, and failing to adequately warn about that its lack of reversal agent or antidote to counteract the drug complications.

The Xarelto injury lawsuit accuses Bayer and Janssen of wrongful death, fraudulent misrepresentation, negligent misrepresentation, strict products liability, negligence, breach of implied and express warranty, fraudulent concealment, and fraud and deceit.

Xarelto Side Effects

Abdominal bleeding
Eye bleeding
Deep vein thrombosis
Gastrointestinal bleeding
Pulmonary embolism
Reduced platelet levels
Abnormal liver function
Brain hemorrhaging
Rectal bleeding
Dizziness
Low blood pressure
Hemorrhaging in the eyes
Nose bleeding
Muscle pain
Headache
Rapid heartbeat
Edema
Bruising

Other Xarelto Lawsuits

A Tennessee family filed a Xarelto lawsuit against Janssen, a Johnson & Johnson subsidiary, on August 14, 2014, seeking $10 million in damages for pain, suffering, personal injuries, wrongful death, and emotional distress. The claimants claim that their father died from the Xarelto complications, suffering irreversible internal bleeding and “was caused to sustain severe and permanent personal injuries, pain, suffering, and emotional distress.”

The ever-growing number of Xarelto side effect lawsuits indicates that the drug was rushed to the market without adequate testing and brazenly promoted without warning of its fatal risks. Lawsuits accuse the drug manufacturers of promoting Xarelto blood thinner as an easy to use and monitor anticoagulant.

Different studies claim that Xarelto side effects may lead to eye bleeding. spontaneous vitreous hemorrhage, stomach or gastrointestinal bleeding.

If you or a loved one has suffered from the drug side effects, you have a potential Xarelto lawsuit arising out of “negligence, concealing of information, misrepresentation, and false advertisement by the manufacturer. Please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney.

October 16, 2015

Arkansas Xarelto Injury Lawsuit: Latest Developments To Know

An Arkansas Xarelto injury lawsuit filed by the family of a deceased woman blames an irreversible brain hemorrhage associated with the blood thinner for her death. The woman, a nursing home resident, fell and injured her head. She was given first aid and her doctor was called next morning, as her condition worsened. The resident died following a massive cerebral bleeding. She was treated with Xarelto, a blood thinner known to cause internal bleeding and without a known antidote.

The Arkansas Xarelto attorney fighting for the plaintiff claims that doctors could not prevent bleeding effects of the anticoagulant for the lack of any reliable reversal agent. Bayer and Johnson & Johnson are facing product liability claim for marketing a dangerous drug with irremediable side effects. The case is a warning for one in every six nursing home residents and millions other taking anticoagulants. Introduction of new-generation blood thinners, such as Pradaxa and Xarelto, without antidotes put them at the increased risk of uncontrolled gastrointestinal, brain, and stomach bleeding and strokes.

The following are important developments to know for anyone considering filing a Xarelto injury lawsuit in Arkansas.

Xarelto Not Safer, Warn Researchers

A recent report citing a French research paper concludes that Xarelto is not superior to warfarin. Published in the American Heart Association journal Circulation, it says that the new anticoagulant holds similar “short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients” as the old blood thinner warfarin. However, it is the lack of antidote that makes Xarelto bleeding side effects more fatal.

According to the Journal for the American Medical Association, Xarelto is too dangerous for kidney patients. It quoted combined guidelines of “the American College of Cardiology, the American Heart Association, and the Society of Thoracic Surgeons” to highlight how new anticoagulants are hazardous for end-stage chronic kidney patients.

Xarelto Lawsuits on the Rise

The second quarter report of Bayer published in July 2015 admits of defending against 1,200 Xarelto bleeding lawsuits. The drug maker faces at least six class actions in Canada. This count excludes about many claims filed against Bayer and Johnson & Johnson in the last one month. Eastern Louisiana federal Judge Eldon Fallon is designated for consolidation of all Xarelto injury lawsuits under the federal MDL provision.

On August 3, four litigations representing 198 claimants joined the MDL claiming wrongful death and injuries attributed to bleeding side effects of the drug.

Statistics Against Xarelto

A study has revealed that 73 percent of persons suffered from side effects during the testing of Xarelto. Reports indicate that “the Einstein studies, the Record studies, and the Rocket AF study” highlighted uncontrolled bleeding risk during the trail phase. But the information was not disclosed to the public and the anticoagulant was promoted as safe.

At least 400 deaths and 3,500 hospitalizations involving Xarelto have been reported since it was approved in 2011. With a surge in prescriptions, the reports of adverse events are on the rise. The drug was responsible for 72 deaths and 896 hemorrhage reports in Germany in 2013. The Institute for Safe Medication Practices included it among the 10 most-frequent side effect reported drugs in 2014.

According to a Milwaukee Journal investigative report, Pradaxa, Xarelto, and Eliquis – three new-generation blood thinners – accounted for 8,000 deaths and 58,000 bleeding injuries in the last four years compared to 700 deaths and 8,000 injures linked to warfarin.

Three-fourths of all Xarelto bleeding reports cite intracerebral hemorrhage, claims the Journal of the American College of Cardiology. The FDA has also warned of blood clots in patients who stop taking the drug abruptly.

Past History of Drug Makers Questionable

The past history of Xarelto makers Bayer and Janssen, a Johnson & Johnson unit, indicates how their defective drugs and suppression of information caused injuries to thousands of users. Janssen settled hundreds of Risperdal lawsuits for $2 billion after plaintiffs accused it of putting profits before people. Bayer is facing over 4,000 Mirena contraceptive injury lawsuits for suppressing safety information. It had settled 9,900 Yasmin and Yaz lawsuits while another 4,000 are awaiting trial. These incidents indicate how both companies give primacy to commercial profit over user safety and suppress data about drug side effects.

Trial Date Set for Aug 2016

The first Xarelto injury lawsuit seeking product liability was filed in January 2014. Within 18 months, over 1,400 claims have been made and a mass tort has also been established. The first bellwether is set for August 1, 2016. It will be followed three more trials on August 22, September 12, and October 17. While the first two will be presided by MDL Judge Eldon Fallon of Eastern district of Louisiana, the other two are slated to be held in Texas and Mississippi federal courts.

If you have a potential Xarelto injury lawsuit in Arkansas (or elsewhere) related to the blood thinner side effects and arising out of “negligence, concealing of information, misrepresentation, and false advertisement by the manufacturer”, please contact us or call on 1-800-632-1404 for a free consultation with our Xarelto attorney.

October 14, 2015October 14, 2015

Xarelto Lawsuit: Claims Get A Boost As Studies Confirm Potential Bleeding Injuries

In a boost to claims by Xarelto lawsuit plaintiffs, two recent studies have confirmed close association between the blood thinner and bleeding injuries. The new-generation anticoagulant was approved by the FDA in 2011. However, it has been blamed for over 500 deaths and more than 4,500 hospitalizations in the last four years. Nearly 1,500 victims of gastrointestinal, cerebral, and other types of irreversible bleeding have sought product liability by filing a Xarelto lawsuit against manufacturers Bayer and Janssen, a Johnson & Johnson subsidiary.

Study Links Xarelto to Eye Bleeding

A study published in the JAMA Ophthalmology journal in June 2015 claims that Xarelto adverse events may lead to eye bleeding. Researchers from Los Angeles-based Keck School of Medicine Eye Institute discovered that “the risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban (generic name of Xarelto) and are taking both anticoagulants simultaneously.”

The study also alleged that at least three users reported spontaneous vitreous hemorrhage following treatment with Xarelto blood thinner. Previous studies had cited that though anticoagulants were not directly responsible for causing eye bleeding, these drugs might increase bleeding due to other pathology. But the recent study discovered occurrence of “bleeding between the lens and retina of the eye.”

Xarelto May Cause Stomach Bleeding

An April 2015 report in the British Medical Journal highlighted the risk of stomach bleeding due to Xarelto blood thinner side effects. This finding based on comparative safety data analysis reinforces claims of hundreds of Xarelto lawsuits alleging gastrointestinal hemorrhage.

Researchers analyzed case studies of 46,000 patients – 39,607 treated with warfarin, 1,649 prescribed Xarelto, and others given Pradaxa – treated with blood thinners between October 1, 2010 and March 31, 2012. Pradaxa is already in the thick of litigation due to its bleeding side effects and fatal injuries. Its manufacturer paid $650 million to settle about 4,000 claims.

The study pointed “as much as a 50% increase in the risk of gastrointestinal bleeding with dabigatran (Pradaxa) compared with warfarin or a more than twofold higher risk of bleeding with rivaroxaban (Xarelto) compared with warfarin.” Until now the makers of Xarelto blood thinner were claiming that their product was safe and without any bleeding effect. But the findings proved otherwise lending credence to claim of hundreds of patients who had fatal and non-fatal stomach bleeding following the drug therapy.

Bleeding Side Effect Claims

Xarelto was approved in 2011 and its popularity is primarily driven by the manufacturer claim that the drug is more convenient and patients need not be monitored for potential bleeding effects. If post-marketing surveys and consumer complaints are to be believed, the blood thinner has proved to be more dangerous than warfarin. Patients above 65 years of age are found to have suffered maximum due to Xarelto bleeding side effects. A 2015 Japanese study claims that 29 of 46 patients treated with the blood thinner are reported for heightened bleeding risks.

If you have a potential Xarelto injury lawsuit related to the blood thinner side effects and arising out of “negligence, concealing of information, misrepresentation, and false advertisement by the manufacturer”, please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney.

September 15, 2015

Xarelto Injury Lawsuits Mount, Study Rejects Anticoagulant Benefits

A Xarelto injury lawsuit filed by a Tennessee family a few weeks ago has sought financial damages from the makers of the blood thinner citing the wrongful death of a patient. The litigation alleges that Bayer and Johnson & Johnson merely “indicated that there was a risk for bleeding and continue selling the drug side-stepping the important issue of reversing the effects of Xarelto should a bleed occur.” The claim is among nearly 1,300 such drug injury lawsuits filed against Bayer in Canada and the United States.

The deceased was prescribed the anticoagulant to treat the risk of heart stroke from non-valvular atrial fibrillation. He died within six months following internal bleeding. According to the Tennessee Xarelto attorney representing the plaintiff, manufacturers have failed to address the issue of irreversible hemorrhaging associated the drug and their claim of superiority of the drug over other anticoagulants is misleading.

Xarelto makers promoted the drug as superior to the long-used blood thinner warfarin. While bleeding caused by warfarin is stopped with vitamin K shots, there is no cure for Xarelto bleeding side effects turn serious and fatal to cause hemorrhage and death. The Institute for Safe Medication Practices claims the blood thinner is the most frequent cause of pulmonary embolism in users. It also found that 44 percent Xarelto complaints reported involve users with hip and knee replacement surgery.

198 Plaintiffs Join Xarelto Litigation

On August 3, four lawsuits representing over 198 Xarelto bleeding side effects were added to the MDL centralized at an Eastern Louisiana federal court. These claimants are unanimous that the anticoagulant led to fatal or near-fatal injuries and deaths. Many of these claims include wrongful death following irreversible bleeding.

The four bundled claims, as presented by Xarelto lawyers, highlight internal bleeding-related side effects, such as

gastrointestinal bleeding
bleeding symptoms visible in urine
brain hemorrhaging
subdural hematoma
pulmonary embolism
bleeding in intestine and kidney
irreversible bleeding
hemoglobin level drop

Study Flays Xarelto Benefit Claims

A study recently reported by Circulation journal of the American Heart Association rejects safety claims by Xarelto manufacturers when compared to warfarin. Researchers discovered that the new-generation blood thinner has no advantage over warfarin as far as “short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients” is concerned.

Based on the French monitoring over 32,000 patients treated with Xarelto, Pradaxa, and warfarin over a period, the study mentions “no significant difference in the rate of bleeding events or arterial thromboembolic events.” It warns that though there is no higher bleeding risk from Xarelto, the absence of a reliable antidote makes bleeding events irreversible and fatal. Doctors struggle to stop bleeding as they are unaware of any effective and approved reversal agent. Longer the internal bleeding, greater is the risk of patient’s death.

An April 2015 study reported by the British Medical Journal cited findings of Johns Hopkins University School of Medicine team to highlight “two-time higher risk” of internal bleeding in patients being treated with Xarelto.

If you have a potential Xarelto injury lawsuit in Tennessee related to the blood thinner side effects and arising out of “negligence, concealing of information, misrepresentation, and false advertisement by the manufacturer”, please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney.

May 24, 2015

Xarelto Attorney Comments About Blood Thinner And Bleeding Side Effects in Kentucky

FREE CASE EVALUATION: 1-800-632-1404

Our team of Xarelto attorneys in Kentucky is reviewing blood thinner side effect claims for filing personal injury litigations without any upfront legal fee and on contingency basis. Contact a Xarelto attorney today for a free case evaluation.

With thousands hospitalized, hundreds of deaths, and over 600 lawsuits, Xarelto is certainly the drug to be rightly placed by the Institute for Safe Medication Practices among the infamous 10 most reported drugs with side effects. In the first half of 2013, MedWatch received reports of at least 200 deaths and hospitalization exceeding 700 patients. Experts fear that this is only the tip of the iceberg, as actual numbers might be in thousands and 90% of these went unreported.

What Are Xarelto Side Effects?

The following major side effects of the drug have been found to be the cause of concern by a Kentucky Xarelto attorney evaluating blood thinner adverse event claims.

Death following fatal internal bleeding
Heightened risk of irreversible bleeding
Gastrointestinal bleeding
Cerebral hemorrhage
Stomach and intestine hemorrhage
Uncontrolled adrenal bleeding
Hemorrhagic stroke
Intracranial hematoma in brain

How Dangerous Is Xarelto Anticoagulant?

Manufacturers in our opinion have been consistently misleading consumers about Xarelto side effect risks until complaints and lawsuits began to be filed. In 2011, the year the drug was introduced, researchers found the blood thinner carried two-fold greater risk of hemorrhage during MAGELLAN Phase 3 trial. However, the information was not made public for a long time. Two years later, the Journal of the American College of Cardiology made similar claims with a warning of potential cerebral, stomach, and intestine bleeding events.

According to the American Heart Association, patients should avoid taking Xarelto anticoagulant, as it increases the risk of internal bleeding by four times. Those without the disorder may still face three-fold enhanced risk. The Journal of Cardiology came out with a study finding that negated the claim that blood monitoring is not required for those on the blood thinner. Researchers found that prolonged thinning effect caused by Xarelto may cause a fatal hemorrhage.

When Reuters interviewed top American cardiologists in 2012 on the efficacy of new generation blood thinners, most of them questioned safety aspects of Xarelto and Pradaxa. There were at least 150 deaths and over 2,000 hospitalizations reported to the FDA in 2012 as Xarelto bleeding side effects. Over 200 died and 700 hospitalized in just first five months of 2013.

New Study Claims Xarelto Unsafe

On April 24, the British Medical Journal reported a study on increased threat of gastrointestinal bleeding due to Xarelto blood thinner. Conducted by researchers from Johns Hopkins, the study analyzed records of 46,000 patients treated with warfarin and the “so-called” new generation anticoagulants. Patients treated with Pradaxa or Xarelto were seen twice more prone to gastrointestinal bleeding than those with warfarin.

Another recent study in JAMA Internal Medicine based on the findings of researchers from California warned against the practice of prescribing blood thinners to low-risk heart rhythm patients unnecessarily. These powerful anticoagulants put them at the greater risk of health hazards due to potential bleeding side effects.

If you have a potential claim related to the blood thinner side effects, please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney in Kentucky.

Contact a Xarelto Injury Lawyer Today.

If you or a loved one was injured or died after ingesting Xarelto, please contact us immediately.

For a Free Case Evaluation:

TOLL FREE: 1-800-632-1404

EMAIL: click here

FILL OUT THIS FORM:

NOTE: Our team of attorneys will review potential cases for all fifty states, including Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington West Virginia Wisconsin and Wyoming.

March 4, 2015

Xarelto Lawsuit Numbers Climb, Outnumber Pradaxa

FREE CASE EVALUATION: 1-800-632-1404

A recent Xarelto lawsuit initiated by a Madison woman has sought over $4.35 million in damages and recovery of other costs. Filed in the St. Clair County Circuit Court, it claims that the plaintiff suffered from internal bleeding as the blood thinner “failed to congeal in a timely manner.” Janssen and Bayer Healthcare spent over $10 million to promote Xarelto as a superior alternative to Warfarin, which is contested by many recent studies. The drug earned about $600 million in sales in 2012.

Our firm has filed a lawsuit involving Xarelto and welcomes the opportunity to discuss a new claim with you.

Bernadette Fuller took the drug, like many other victims, to subdue deep vein thrombosis and prevent strokes. However, she became ill after ingesting the drug and had severe internal bleeding that was irreversible in the absence of any Xarelto blood thinner antidote. Her Xarelto attorney accused the manufacturers of hyping the positive research findings without highlighting “the increased risk of gastrointestinal bleeding and bleeding that required transfusion among other serious bleeding concerns.”

Xarelto bleeding side effects result in people with greater chance of hemorrhage risk, according to three studies – “the Einstein studies, the Record studies, the Rocket AF study” – carried out during the clinical trial phase. However, Bayer and Janssen deliberately suppressed the adverse anti-coagulation effects while running promotional campaigns exaggerating the drug effectiveness, which led to injuries and deaths.

The Xarelto blood thinner lawsuit evokes “product liability, intentional infliction of emotional distress, negligent infliction of emotional distress, common law fraud, negligence, negligent misrepresentation, fraudulent misrepresentation and strict products liability” to sue the manufacturers citing personal injuries, medical costs, wage loss, and diminished life following illness.

Xarelto Complaints Outnumber Pradaxa

Xarelto have overtaken Pradaxa both in sales and complaints. The blood thinner accounted for at least 2,081 serious injuries and 151 deaths in 2012. According to the Institute for Safe Medication Practices, the drug was among the “10 most frequently named” medications with adverse events.

In 2014, Xarelto exceeded Pradaxa in number of prescriptions and consequently, the number of complaints eclipsed Pradaxa. A May 2014 ISMP report indicated at least 200 patients died and 680 suffered grievous injuries in the first four months of 2013 following Xarelto bleeding side effects. The figures may go up many times to thousands, as only one-tenth of adverse events were reported to the FDA. The report also warned that Xarelto adverse events were “steadily increasing” with a rise in the use by consumers.

Over 4,000 Pradaxa lawsuits filed against its maker Boehringer Ingelheim were settled in May 2014 for $650 million. In December 2014, the USMDL ordered pre-trial centralization of two dozens of Xarelto lawsuits filed in 10 different states in the court of Judge Eldon E. Fallon of Louisiana Eastern District.

Study Rejects Stated Xarelto Advantage Over Warfarin

A Canadian study has claimed that new generation blood thinner Xarelto is “no safer” that Warfarin oral anti-coagulant, which has been prescribed for over six decades. Published in the Canadian Journal of Cardiology last month, the report was based on an analysis of safety profiles of Pradaxa, Warfarin, and Xarelto blood thinners at Ontario-based Southlake Regional Health Centre.

Researchers found identical safety profiles and side effects of blood thinners while exploring over 900 case studies of users. They found “no significant difference” in bleeding events and action off drugs during the treatment of atrial fibrillation. It blunts the manufacturer claim that Xarelto, which is expensive and with potential more side effects, has an edge over Warfarin.

Xarelto lawsuits filed claim that the drug leads to “uncontrollable bleeding among users” and it become life-threatening in the absence of reversal antidote.

If you have a potential claim related to the blood thinner side effects, please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney.

Contact a Xarelto Injury Lawyer Today.

If you or a loved one was injured or died after ingesting Xarelto, please contact us immediately.

For a Free Case Evaluation:

TOLL FREE: 1-800-632-1404

EMAIL: click here

FILL OUT THIS FORM:

March 2, 2015March 2, 2015

Xarelto Lawsuit: Philadelphia Court orders for mass tort docket

FREE CASE EVALUATION: 1-800-632-1404

A Xarelto lawsuit multi-district litigation (MDL) has been set up in Pennsylvania following a January 21, 2015 Order of the Philadelphia Court of Common Pleas. At least 75 litigations are filed in the state claiming irreversible bleeding and fatal side effects linked to ingestion of the blood thinner. The establishment of the mass tort means all present and future claims submitted by a Xarelto attorney in the state will be centralized for consolidated pre-trial proceedings at the court of Judge Kevin Dougherty.

Janssen and Bayer Healthcare are named as defendants in over two-dozen Xarelto bleeding side effect litigations. The numbers of lawsuits are expected to amplify significantly considering the fact that the FDA received reports of over 200 deaths and about 700 bleeding injuries associated with the blood thinner between January and May 2013. Actual figures (unreported) may run into thousands. The 2012 figures, 151 died and 2,081 hospitalized, led the Institute for Safe Medication Practices to name Xarelto as one of the “10 most frequently named” drugs for side effects.

Our firm has filed a Xarelto related lawsuit in Tennessee Federal Court.

Xarleto Lawsuit Blames Manufacturer

A recent Xarelto lawsuit filed in a West Virginia federal court alleges that the manufacturers ignored research reports highlighting greater “risk of gastrointestinal bleeding and even the need for blood transfusion to eliminate irreversible side effects” associated with the blood thinner and marketed the drug despite potential threats to users.

The plaintiff, a woman, was prescribed the drug after she was diagnosed with atrial fibrillation. She had gastrointestinal bleed that did not stop with any antidote and ultimately she required blood transfusion to prevent fatal conditions. According to the Xarleto attorney representing her, “the Institute for Safe Medication Practices noted that, even during the approval process, ‘FDA (reviewers) also questioned the convenient once-a-day dosing scheme … (saying) blood level studies had shown peaks and troughs that could be eliminated by twice-a-day dosing…’ and in the event of hemorrhagic complications there is no available reversal agent.”

The Xarleto product liability lawsuit seeks damages based on “negligence, fraudulent misrepresentation, fraudulent concealment, negligent misrepresentation, fraud and deceit, violation of the West Virginia Consumer Credit & Protection Act and loss of consortium.”

Study Rejects Xarleto Superiority Over Warfarin

A Japanese study reported in the Journal of Cardiology has negated the manufacturer claim that using Xarelto does not require blood monitoring, which is an essential requirement for those on Warfarin. Researchers examined 136 patients administered the blood thinner under observation and discovered that “, the drug caused a prolonged “thinning” effect, making them more likely to experience serious bleeding events” within two weeks. They advised for blood monitoring as in the case of Warfarin to prevent the bleeding risk caused by prolonged “thinning” effect from leading to fatal hemorrhage in patients and hospitalization of users.

Xarelto Bleeding Side Effect

Death due to irreversible internal bleeding
Gastrointestinal hemorrhage
Stomach bleeding
Stroke due to hemorrhage
Adrenal hemorrhage
Cerebral hemorrhage
Intracranial hematoma in brain

Xarelto blood thinner was approved in 2011. Despite carrying a significant internal bleeding risk, the manufacturers promoted the drug as a next-generation anticoagulant with significant benefit over Warfarin, another blood thinner extensively used for decades. While positive results were advertised, the drug makers kept negative clinical findings away from public domain, which has been cited in most Xarleto lawsuits. Again, Bayer and Janssen introduced it and engaged in aggressive marketing efforts without suggesting any effective antidote to reverse serious bleeding effects, if happens.

If you have a potential Xarelto lawsuit related to the blood thinner side effects, please contact us or call on 1-800-632-1404 for a free consultation with our experienced Xarelto attorney.

Contact a Xarelto Injury Lawyer Today.

If you or a loved one was injured or died after ingesting Xarelto, please contact us immediately.

For a Free Case Evaluation:

TOLL FREE: 1-800-632-1404

EMAIL: click here

FILL OUT THIS FORM:

December 12, 2014

Xarelto Lawsuit Filed Over Brain Hemorrhage

Xarelto Lawsuits for the Xarelto Blood Thinner

FREE CASE EVALUATION: 1-800-632-1404

Patients using Xarelto blood thinner are at the enhanced risk of brain hemorrhage and the danger assumes grievous propotions in the absence of any effective agent to reverse the drug effects. A Xarelto lawsuit filed in a Louisiana eastern district federal court claims that the plaintiff suffered from serious and life-threatening brain hemorrhage after he was treated with the drug. Manufactured by Bayer and marketed by Janssen, the blood thinner has been cited for causing serious internal bleeding complications.

According to the lawsuit, James J. Brien was prescribed Xarelto in April 2013 following diagnosis of non-valvular atrial fibrillation, a cardiac complication. He was hospitalized following brain hemorrhage in September 2014 and endured a paralysis attack. Though he was discharged after months of recovery and rehab process, the patient suffered from walking disability. The plaintiff took the blood thinner as directed to avert heart strokes, but he ended up in damage to his brain unaware of side effect hazards, his Xarelto attorney claims.

It is unsuspecting for the plaintiff to predict adverse events, such as internal bleeding, while he started taking the drug, as there was no such information by the manufacturer. He came to know about it only after research reports hinted at serious bleeding events and filed a Xarelto lawsuit seeking product liability and recovery of damages.

Xarelto Blood Thinner Hemorrhage Risks

In June 2014, a Xarelto lawsuit filed in a Florida court linked the blood thinner to fatal subdural hemorrhage condition. William Packard died of uncontrollable brain hemorrhage within six months of taking the drug to treat atrial fibrillation. His family has sought $10 million in economic and non-economic damages from the blood thinner manufacturers. It followed many similar claims blaming the medication for cerebral hemorrhage, intracranial bleeding, and gastrointestinal bleeding.

Stroke or rupture in blood vessels spills out the blood into the skull, tissues, and membranes. Patients experience intracranial pressure, irritation, inflammation, swelling, and development of hematoma. As a result the blood-oxygen supply to the brain was prevented and brain cells can die. Such type of cerebral hemorrhage has the potential to cause permanent brain damage and cognitive complications, such as vision loss, seizures, confusion, and coma.

Xarelto attorneys claim that the medication has the ability to “interrupt the intrinsic and extrinsic pathways of the blood coagulation cascade” for 24 hours and it has the potential to worsen patient conditions with excessive, life-threatening bleeding, as there is no medication at present to counter its anticougaltion properties. Due to the drug’s ability to “bind to plasma proteins tightly,” even dialysis proves to be futile to cleanse the body of the medication. In Germany, at least 72 people and 890 had died hemorrhage in 2013 linked to Xarelto internal bleeding.

In 2013, the American Heart Association warned of three-fold greater internal bleeding risk in patients using the blood thinner. The hazard goes up for patients with Acute Coronary Syndrome. Following reports of high-bleeding cost vis-à-vis the drug efficacy, the FDA refused to allow Xarelto as a mode of treatment for those suffering from Acute Coronary Syndrome.

In December 2013, the Journal of the American College of Cardiology cited research findings highlighting that 74% of Xarelto internal bleeding events are intracerebral hemorrhage type.

Possible Xarelto Brain Hemorrhage Injuries

Wrongful death
Damage to brain
Swelling and inflammation of brain
Intracranial hematoma in brain
Seizures
Coma
Loss of vision
Intracranial pressure

Xarelto Lawsuit

The FDA approved Xarelto blood thinner in 2011 to treat potential risk of blood clotting that can cause heart attack, pulmonary embolism, thrombolic events, and stroke in patients. However, research studies have found that the drug does not offer any significant advantage over other and existing anticoagulants. Additionally, it poses higher risk of frequent brain, stomach, and intestine bleeding that can be life threatening. Xarelto attorneys claim that overpromotion of the drug as superior and suppression of side effects by manufacturers misled their clients to use the blood thinner and suffer from fatal complications.

About 30 Xarelto lawsuits have been filed in 14 states citing “negligence, concealing of information, misrepresentation, and false advertisement” by the manufacturer. If you have a potential claim related to the blood thinner side effects, please contact us or call on 1-800-632-1404 for a free consultation with an Xarelto attorney.

Contact a Xarelto Injury Lawyer Today.

If you or a loved one was injured or died after ingesting Xarelto, please contact us immediately.

For a Free Case Evaluation:

TOLL FREE: 1-800-632-1404

EMAIL: click here

FILL OUT THIS FORM:

November 21, 2014November 21, 2014

Xarelto Lawsuit: Plaintiffs Allege Life-Threatening Bleeding Linked to Blood Thinner

FREE CASE EVALUATION: 1-800-632-1404

A Xarelto lawsuit filed by an 87-year-old man claims that he experienced life-threatening internal bleeding caused by the blood thinner. The litigation filed in a California northern district federal court in October 2014 cites gastrointestinal hemorrhage as one of the blood thinner side effects. The plaintiff was treated with the anticoagulant drug for some months until October 2014, when he suffered from uncontrolled hemorrhage in the absence of any antidote to the drug, the Xarelto attorney representing the man claims.

The litigation followed a similar Xarelto internal bleeding lawsuit filed by a California woman in August 2014. Shirley Boynton began using the blood thinner in April 2012. She had life-threatening bleeding within six months that resulted in debilitating and permanent injuries. Had she been aware of such potential side effects or read about hemorrhaging risk on its label, the plaintiff would have avoided it, according to her Xarelto lawsuit filed in a New York district court.

The two lawsuits have named Bayer and Johnson and Johnson as defendants and seek $10 million in damages.

Xarelto Lawsuit: Blood Thinner Side Effects Research

The FDA approved Bayer’s oral anticoagulant Xarelto, which contains rivaroxaban, in July 2011. Marketed by Janssen, the drug is prescribed to people with knee surgery or others at the higher risk of blood clotting. It inhibits factor Xa, which in turn “interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade.” In November 2011, the drug was allowed to treat patients suffering from atrial fibrillation or clots in blood arteries, a possible indication of stroke.

However, researchers have questioned the efficacy of the drug advertised by the manufacturers. Though the impact is slated to last 8 to 12 hours, the anticougaltion properties in the body continue to remain subdued for 24 hours. The absence of any readily available antidote makes the Xarelto blood thinner even more dangerous and may lead to excessive, life-threatening bleeding, as cited by many product liability lawsuits.

According to the American Heart Association, Xarelto is likely to cause the three-time higher risk of internal bleeding acute ill patients. The risk is four-time more in those with preexisting Acute Coronary Syndrome, asserts one of its reports presented in November 2013.

The German newsmagazine Der Spiegel carried a report in 2013 that linked Xarelto blood thinner to 72 deaths and 896 hemorrhage events between January and October 2013. The figures for 2012 were 58 deaths and 692 internal bleeding complaints.

A comparative study by Johnson & Johnson conducted in April 2011 discovered that patients treated with oral anticoagulant Xarelto for more than 35 days twice more prone to developing bleeding adverse events compared to Lovenox, an injectable blood thinner with enoxaparin as the main ingredient.

The ROCKET AF clinical trial results reported the Journal of the American College of Cardiology in December 2013 also demonstrated bleeding or hemorrhage as the most common Xarelto side effect. Funded by the manufacturers, the study covered 14,000 patients treated with Xarelto and Warfarin blood thinners over a two-year period. While both drugs were found to cause identical side effects, Xarelto was not superior to Warfarin, the researchers concluded.

It was also discovered that Xarelto-induced hemorrhage has less impact in the brain, but had significant bleeding rate for stomach and intestine.

Xarelto Blood Thinner Side Effects

Cerebral hemorrhage
Gastrointestinal bleeding
Stroke
Wrongful death
Stomach and adrenal bleeding
Subarachnoid, subdural, and extradural hemorrhages
Swelling leads to intracranial hematoma in brain

Xarelto Lawsuit

A motion was filed early October 2014 to centralize all Xarelto hemorrhage lawsuits filed in different states. At that time about two dozen such litigations citing bleeding injuries were pending at the federal judicial system spread over 10 states. The plaintiffs have sought MDL pretrial consolidation at the Southern District Court of Illinois presided by David R. Herndon. The U.S. JPML planned to meet in Charleston, SC, on December 4 or in Miami, FL, on January 29 is expected to take a look at consolidation.

Meanwhile, there has been a noticeable increase in the filing of Xarelto lawsuits claiming wrongful death, fatal and non-fatal internal bleeding, coma, cerebral hemorrhage, and other types of injuries. The actual litigation numbers may run in hundreds as many affected individuals contacting Xarelto lawyers to examine the product liability claims.

For a free consultation with our experienced Xarelto attorneys, please contact us or call on 1-800-632-1404.

Contact a Xarelto Injury Lawyer Today.

If you or a loved one was injured or died after ingesting Xarelto, please contact us immediately.

For a Free Case Evaluation:

TOLL FREE: 1-800-632-1404

EMAIL: click here

FILL OUT THIS FORM: